Glenmark Pharmaceuticals Moat Analysis: Score & Risks
Glenmark Pharmaceuticals Ltd.
A first-pass moat teardown of Glenmark Pharmaceuticals Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence.
Glenmark Pharmaceuticals Ltd. scores 5.23 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Our Telma franchise is the No. 1 brand franchise in the Indian Pharmaceutical Market (IPM), as per IQVIA MAT March 2025.”
“the litigation that we paid on the Zetia piece, almost 498 crores”
“Cost leadership across products through careful monitoring and continuous effort”
“The Company makes conscious efforts to launch new value added products with some differentiation i.e. improvised products which can fetch better pricing.”
“With Alex, our over 28-year-old brand of cough medicine, we have improved patient adherence to therapy with differentiated offerings for the entire age spectrum from children to elderly.”
“The US generics market continues to be challenging with greater price erosion, consolidation of the supply chain and increasing number of competitors.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion